Planimetric and Histological Study of the Aortae in Atherosclerotic Chickens Treated with Nifedipine, Verapamil and Diltiazem

Total Page:16

File Type:pdf, Size:1020Kb

Planimetric and Histological Study of the Aortae in Atherosclerotic Chickens Treated with Nifedipine, Verapamil and Diltiazem Histol Histopathol (2003) 18: 1027-1033 Histology and http://www.hh.um.es Histopathology Cellular and Molecular Biology Planimetric and histological study of the aortae in atherosclerotic chickens treated with nifedipine, verapamil and diltiazem B. García Pérez1, I. Ayala2, M.T. Castells3, J.F. Madrid3, M.R. Ortega1, J.V. Ortega4, J. Ballesta,3 J. Fernández Pardo5 and M. Valdes1 1Clinical Universitary Hospital, Virgen de la Arrixaca, 2Department of Veterinary Medicine, College of Veterinary Medicine, University of Murcia, Campus de Espinardo, 3Department of Cell Biology, Medical School, University of Murcia, 4Los Arcos Hospital, Santiago de la Ribera and 5General Hospital, Murcia, Spain Summary. Calcium appears to be involved in many of Introduction the cellular events which are thought to be important in atherogenesis. Calcium channel blockers have been Atherosclerosis and its consequences continue to be shown to reduce arterial lipid accumulation in animals the major cause of death in Europe and the United States without altering serum cholesterol. Avian models of (Sans et al., 1997; Kesteloot et al., 2002). It appears to atherosclerosis offer economic and technical advantages develop over much of the lifetime of a patient, and is over mammalian models. related to well-known risk factors, especially heredity, In this study, we examine the effects of nifedipine, hyperlipidemia, hypertension, cigarette smoking and verapamil and diltiazem at clinical and higher doses, on diabetes mellitus (Peeters et al., 2002). the extent of atherosclerosis of egg-fed chickens. In Animals have been used as experimental models in order to assess the extent of atherosclerosis atherosclerosis-related research since the turn of the past quantitatively, the aortic lesions of the thoracic and century (Narayanaswamy et al., 2000). Avian models of abdominal aorta, aortic arch and supraaortic regions atherosclerosis helped pioneer the study of vascular were measured by planimetry. Atherosclerotic lesions biology, and offer economic and technical advantages were evaluated histologically. Statistically significant over mammalian models (Wang et al., 1999). The egg- reductions in the lipid deposition of the aorta were found fed chicken is a good animal model for the study of in all the treated groups. The extent and distribution of atherosclerosis research (Siller, 1961; Gosling et al., atherosclerotic lesions were decreased in a significant 1969; Valdés, 1976; García Pérez et al., 2002). The way by verapamil, nifedipine and diltiazem. The higher chicken is small and suitable for prolonged laboratory the dosage used, the higher the regression of the investigation; able to develop spontaneous atherosclerotic lesions. At clinical dosage, nifedipine atherosclerosis; capable of producing atherosclerosis showed the highest decrease of the lesions. In addition, after cholesterol feeding with elevated the chicken atherosclerosis model has proved itself hypercholesterolemia and there is no essential difference useful and very suitable for in vivo drug intervention between vascular lesions seen in chickens as a result of studies. cholesterol diet and that of atherosclerosis observed in man (Wong, 1975). The rabbit, also free of spontaneous Key words: Atherosclerosis, Nifedipine, Verapamil, atherosclerosis, is extremely sensitive to lipid-rich diets, Diltiazem, Chicken but the lesions induced resemble more a xanthomatosis than an atherosclerosis (Hadjiisky et al., 1991). The monkey and pig, which are phylogenetically close to man, develop spontaneous atherosclerosis exacerbated by lipid-rich diets or other procedures, but the cost and problems of upkeep make these two models inaccessible to most laboratories (Hadjiisky et al., 1991). The utility Offprint requests to: Dr. Ignacio Ayala, Department of Veterinary of transgenic mouse models of atherosclerosis, such as Medicine, College of Veterinary Medicine, University of Murcia, Campus the apolipoprotein E (apoE)-deficient mouse and the low de Espinardo s/n, 30100 Murcia, Spain. Fax: 34-968-364147. e-mail: density lipoprotein (LDL) receptor-negative mouse, for [email protected] the evaluation of antiatherosclerotic agents has yet to be 1028 Effect of calcium antagonists on chicken atherosclerosis determined. Paradoxical observations raise an important given ad libitum. issue relating to interpretation of the results of drug Each of the 8 groups consisted of 10 animals which intervention studies in genetically-derived mouse models were treated as follows. Group A: normal diet. Group B: (Bocan, 1998). atherogenic diet. Group C: atherogenic diet and Calcium appears to be involved in many of the nifedipine at clinical doses (3 mg/kg/day in two doses). cellular events, which are thought to be important in Group D: atherogenic diet and nifedipine at high doses atherogenesis (Rouleau et al., 1983; Catapano, 1997; (30 mg/kg/day in two doses). Group E: atherogenic diet Miller, 2001; Pepine and Handberg, 2001). Compounds and verapamil at clinical doses (4 mg/kg/day in two which decrease intracellular calcium by reducing doses). Group F: atherogenic diet and verapamil at high calcium influx have been shown to suppress doses (40 mg/kg/day in two doses). Group G: atherogenesis in experimental atherosclerosis (Rouleau atherogenic diet and diltiazem at clinical doses (6 et al. 1983, Ginsburg et al. 1983; Catapano, 1997). mg/kg/day in two doses). Group H: atherogenic diet and Hypocalcemic agents, calcium channel blockers and diltiazem at high doses (60 mg/kg/day in two doses). other calcium antagonists have been shown to reduce For all experiments, the calcium entry blockers arterial lipid accumulation in several animals without nifedipine, verapamil and diltiazem were prepared altering serum cholesterol, blood pressure or heart rate weekly. The clinical doses were equivalent to the (Kramsch et al. 1980). Calcium antagonists have standard doses of each drug for adult humans. The high protective effects against ischaemia and antiatherogenic doses were 10 times the clinical doses. Animals were potential (Zannad, 2000), and may have beneficial weighed weekly, in order to calculate the doses. Water effects on the development of atherosclerosis, such as was used for the solution of verapamil and diltiazem; the inhibition of vascular smooth muscle cell polyethyleneglycol for nifedipine. An ultrasound bath proliferation and migration, inhibition of calcium influx was needed for the complete solution of diltiazem. into the vascular wall, reduction of extracellular matrix Nifedipine was protected from light in dark bottles. synthesis, promotion of uptake and breakdown of low- Medications (1 ml) were administered (force-fed) density lipoproteins, protection of lipoproteins from daily at 7 a.m. and 7 p.m. for two months (at the end the oxidative modification, maintenance of endothelial cell chickens were 81 days old). Polyethylenglycol was function, inhibition of platelet activation and reduction administered to the control groups as placebo. of blood pressure (Schachter, 1997). They also appear to have antioxidant effects in addition to their potent Tissue preparation vasorelaxant properties (Sobala et al., 2001). However, there are very few experimental studies The chickens were sacrificed after two months of comparing different kinds of calcium entry blockers and treatment. Traumatic damage to the arterial endothelium most of them use much higher doses than the clinical and intima was avoided by reducing the duration of the ones (Henry and Bentley, 1981; Ginsburg et al., 1983; animals’ dissection to less than 15 minutes. The aortae Catapano, 1997). Besides, there are no serial studies of five animals were removed, cleaned of surrounding which focus on the use of calcium entry blockers in tissue, opened and stained for lipid with Sudan III as avian models of atherosclerosis. described by Holman et al. (1958). Briefly, after washing In this work, we examine the effects of three calcium in 70% alcohol for 2 hours, samples were incubated in entry blockers (nifedipine, verapamil and diltiazem), at 0.3% Sudan III in 70% alcohol for 2 days at 37 ºC. human clinical and higher doses, on the extent of Dissected aortas were then washed and the luminal atherosclerosis of chickens fed a high-cholesterol diet. surface of the aortae was photographed by means of a Therefore, new histological and planimetric data Reprovit (Leitz Wetzlar, Germany) and Gold 100-2- concerning reduction in the lipid deposition of the aorta Kodak 5095 film. The atherosclerotic involvement was by the use of several calcium channel blockers in evaluated in the thoracic and abdominal aortae, aortic chickens are provided in this study. arch and supraaortic regions by computerized planimetry (Hewlett-Packard 85-B computer and HP 9111-A digital Materials and methods ultrasonic tracer). The percentage of the sudanophilic area was quantified (sudanophilic area/ aortic area). Experimental procedure Samples of five animals of each group were fixed for light and electron microscopy. For light microscopy, Eighty male 3-week-old White Leghorn chickens samples were fixed in 10% formalin in 0.1M phosphate- were housed under controlled conditions and randomly buffered saline, pH 7.4 (PBS), for 12 hours. After assigned to 8 groups and 2 kinds of diet (during the first fixation, they were processed for inclusion in paraffin 3 weeks of life all of them received a standard growing wax and 5 µm-thick paraffin sections were cut. Sections diet). Diet A (normal): a standard grower mash. The were stained
Recommended publications
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • United States Patent (19) 5
    United States Patent (19) 11 Patent Number: 5,073,379 Klimesch et al. 45) Date of Patent: * Dec. 17, 1991 54 CONTINUOUS PREPARATION OF SOLID (56) References Cited PHARMACEUTICAL FORMS U.S. PATENT DOCUMENTS 2,829,756 4/1958 Gercke et al. ..... ... 198/25 75 Inventors: Roger Klimesch, Alsbach-Haehnlein; 3,089,818 5/1963 Stone .......... ... 424/78 Gerhard Bleckmann, Lampertheim; 3,432,592 3/1969 Speiser ................................ 424/468 Karl-Peter Farwerck, Worms; Lothar 4,072,551 2/1978 Dabal et al. ......................... 424/439 Schlemmer, Maxdorf. Axel Sanner, 4,349,53 9/1982 Mlodozeniec et al. ............. 424/443 Frankenthal, all of Fed. Rep. of 4,631,284 12/1986 Salpekar et al. .................... 514/849 Germany 4,661,521 4/1987 Salpekar et al. .................... 424/465 73 Assignee: BASF Aktiengesellschaft, FOREIGN PATENT DOCUMENTS 0240904 10/1987 European Pat. Off. Ludwigshafen, Fed. Rep. of 01284.09 6/1919 United Kingdom . Germany - 0640440 7/1950 United Kingdom . *) Notice: The portion of the term of this patent Primary Examiner-Thurman K. Page subsequent to Jan. 31, 2006 has been Assistant Examiner-James M. Spear disclaimed. Attorney, Agent, or Firm-Oblon, Spivak, McClelland, Maier & Neustadt 21) Appl. No.: 398,663 (57) ABSTRACT A mixture of one or more pharmaceutical active com (22 Filed: Aug. 25, 1989 pounds and one or more thermoplastic polymers is tabletted by a process in which the mixture is extruded 30) Foreign Application Priority Data and the still moldable extrudate is pressed to give tab lets, between two belts, or a belt and a roller, which Sep. 7, 1988 (DE) Fed.
    [Show full text]
  • Calcium Channel Blockers for Bipolar Disorder: a Systematic Review And
    Calcium channel blockers for bipolar disorder: a systematic review and meta-analysis (Protocol) Andrea Cipriani,1 Mary-Jane Attenburrow,1 James Stefaniak,1 Kate Saunders,1 Sarah Stockton,1 Priyanka Panchal,1 Paul Harrison,1 John R Geddes1 1 Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK (Version 2.1, March 2015) Background Bipolar disorder is a chronic, recurrent affective disorder in which there are mood swings between elevation and depression that are not caused by medication or physical comorbidities (Phillips and Kupfer 2013). The lifetime prevalence rate for bipolar disorder is approximately 1% in the general public; intriguingly, prevalence rates of bipolar disorder remain relatively constant between countries despite more widely varying rates of major depression (Merikangas 2011). Whilst the aetiopathogenesis of bipolar disorder has not been fully elucidated, there is clearly a strong genetic component (Craddock and Sklar 2013). Mood episodes normally start in the third decade of life and so bipolar disorder causes severe social distress; indeed, it accounted for more than 12 million Disability-Adjusted Life Years globally in 2010 alone (Murray 2012). Needless to say, such disability poses significant economic costs (Gonzalez-Pinto, Dardennes et al. 2010). Pharmacological treatment options are of great importance in bipolar disorder (Geddes and Miklowitz 2013). Treatment is invariably long term and often lifelong. Lithium remains a first line mood stabiliser in the preventative treatment of bipolar mood episodes (Geddes and Miklowitz 2013). However, approximately one third of patients do not respond adequately to lithium therapy. Various second generation antipsychotics and anticonvulsants were often trialled but with varying, not to say limited, efficacy (Geddes and Miklowitz 2013).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow Et Al
    US 20100184806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow et al. (43) Pub. Date: Jul. 22, 2010 (54) MODULATION OF NEUROGENESIS BY PPAR (60) Provisional application No. 60/826,206, filed on Sep. AGENTS 19, 2006. (75) Inventors: Carrolee Barlow, Del Mar, CA (US); Todd Carter, San Diego, CA Publication Classification (US); Andrew Morse, San Diego, (51) Int. Cl. CA (US); Kai Treuner, San Diego, A6II 3/4433 (2006.01) CA (US); Kym Lorrain, San A6II 3/4439 (2006.01) Diego, CA (US) A6IP 25/00 (2006.01) A6IP 25/28 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) SUGHRUE MION, PLLC A6IP 25/22 (2006.01) 2100 PENNSYLVANIA AVENUE, N.W., SUITE 8OO (52) U.S. Cl. ......................................... 514/337; 514/342 WASHINGTON, DC 20037 (US) (57) ABSTRACT (73) Assignee: BrainCells, Inc., San Diego, CA (US) The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system (21) Appl. No.: 12/690,915 including by stimulating or increasing neurogenesis, neuro proliferation, and/or neurodifferentiation. The disclosure (22) Filed: Jan. 20, 2010 includes compositions and methods based on use of a peroxi some proliferator-activated receptor (PPAR) agent, option Related U.S. Application Data ally in combination with one or more neurogenic agents, to (63) Continuation-in-part of application No. 1 1/857,221, stimulate or increase a neurogenic response and/or to treat a filed on Sep. 18, 2007. nervous system disease or disorder. Patent Application Publication Jul. 22, 2010 Sheet 1 of 9 US 2010/O184806 A1 Figure 1: Human Neurogenesis Assay Ciprofibrate Neuronal Differentiation (TUJ1) 100 8090 Ciprofibrates 10-8.5 10-8.0 10-7.5 10-7.0 10-6.5 10-6.0 10-5.5 10-5.0 10-4.5 Conc(M) Patent Application Publication Jul.
    [Show full text]
  • KCAS Method List
    Validated Method List Analyte Matrix LLOQ Unit Platform Acebutolol / Diacetolol Human Plasma 5 ng/mL HPLC/UV Acetaminophen (APAP) Human Plasma 0.1 mcg/mL LC-MS/MS Acetaminophen / Tramadol Human Plasma 100 / 5 ng/mL LC-MS/MS Acetylsalicylic Acid / Salicylic Acid Human Plasma 0.25/ 0.75 mcg/mL HPLC/UV Acid Glycoprotein, α1 Human Plasma 3.5 ng/mL ELISA Acyclovir Human Plasma 20 ng/mL HPLC/FL Acyclovir Human Urine 1 mcg/mL HPLC/FL Adipenectin Human Serum 0.8 ng/mL ELISA Alkaline Hematin (see Menstrual Blood) Menstrual Products Allopurinol / Oxypurinol Human Plasma 50 / 100 ng/mL LC-MS/MS Alprazolam / α-Hydroxyalprazolam Dog Plasma 0.5 / 0.5 ng/mL LC-MS/MS Alprazolam / α-Hydroxyalprazolam Human Plasma 0.5 / 0.5 ng/mL LC-MS/MS Aluminum Human Plasma 5 / 2 ng/mL HPLC Aluminum Human Urine 5 / 2 ng/mL HPLC Amikacin Human Serum 0.15 mcg/mL LC-MS/MS Amikacin Human Urine 0.5 mcg/mL LC-MS/MS ng on Aminosalicylic Acid, 5- Human Feces 1 HPLC/FL col Aminosalicylic Acid, 5- Human Urine 2 mcg/mL HPLC/FL Aminosalicylic Acid, 5- Rat Plasma 10 ng/mL LC-MS/MS Aminosalicylic Acid, 5- / N-Acetyl-5-Aminosalicylic Human Plasma 10 / 10 ng/mL HPLC/FL Acid Amiodarone / Desethylamiodarone Human Plasma 10 ng/mL LC-MS/MS Amitriptyline Human Plasma 200 pg/mL LC-MS/MS Amlodipine Human Plasma 50 pg/mL LC-MS/MS Amlodipine Human Plasma 0.15 ng/mL LC-MS/MS Anipamil Human Plasma 5 ng/mL HPLC/FL Aprepitant Human Plasma 10 ng/mL LC-MS/MS Aspirin (See Acetylsalicylic Acid) Human Plasma 0.25 ng/mL HPLC/UV Atenolol Human Plasma 10 ng/mL LC-MS/MS Atenolol Human Urine 250 ng/mL LC-MS/MS
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.201923 B1 Van Lengerich (45) Date of Patent: Apr
    US007201923B1 (12) United States Patent (10) Patent No.: US 7.201923 B1 van Lengerich (45) Date of Patent: Apr. 10, 2007 (54) ENCAPSULATION OF SENSITIVE LIQUID 5,074,902 A * 12/1991 Connick, Jr. et al. COMPONENTS INTO A MATRIX TO 5,075,058 A 12/1991 Chan et al. OBTAIN DISCRETE SHELF-STABLE 5,079,012 A 1/1992 Lengerich et al. PARTICLES 5,087,461 A 2f1992 Levine et al. 5,106,639 A 4, 1992 Lee et al. (75) Inventor: Bernhard H. van Lengerich, 5,118,513 A 6/1992 Mehansho et al. Plymouth, MN (US) 5, 183,690 A 2f1993 Carr et al. 5,262,167 A * 11/1993 Vegesna et al. (73) Assignee: General Mills, Inc., Minneapolis, MN 5,296,000 A 3, 1994 Darmont et al. (US) 5,314,692 A 5/1994 Haarasilta et al. 5,320,669 A * 6/1994 Lim et al. (*) Notice: Subject to any disclaimer, the term of this 5.431,929 A 7/1995 Yatka et al. patent is extended or adjusted under 35 5,458,823. A 10, 1995 Perkins et al. U.S.C. 154(b) by 0 days. 5,466,460 A 11/1995 McMahon et al. (21) Appl. No.: 09/233,443 (Continued) (22) Filed: Jan. 20, 1999 FOREIGN PATENT DOCUMENTS Related U.S. Application Data DE 37 38 042 A 5, 1988 (60) Provisional application No. 60/109,696, filed on Nov. 24, 1998, provisional application No. 60/103,700, (Continued) filed on Oct. 9, 1998. OTHER PUBLICATIONS (51) Int. Cl. Per Artusson et al., “Characterization of Polyacryl Starch A6 IK 9/14 (2006.01) Microparticles as Carriers for Proteins and Drugs,” Journal of A6 IK 47/36 (2006.01) Pharmaceutical Science, vol.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Protective Effect of Pretreatment with the Calcium Antagonist Anipamil on the Ischemic-Reperfused Rat Myocardium: a Phosphorus-31 Nuclear Magnetic Resonance Study
    30h JACC Vol. 11 , No. 5 1087 May 1988: 1087-93 Protective Effect of Pretreatment With the Calcium Antagonist Anipamil on the Ischemic-Reperfused Rat Myocardium: A Phosphorus-31 Nuclear Magnetic Resonance Study J. HANS KIRKELS, MD, TOM J.c. RUIGROK, PHD, FACC, CEES J.A. VAN ECHTELD, PHD , FRITS L. MEIJLER, MD , FACC Utrecht, The Netherlands To assess whether the prophylactic administration of ani­ mals recovered significantly better than untreated hearts pamil, a new calcium antagonist, protects the heart against with respect to replenishment of ATP and creatine phos­ the effects of ischemia and reperfusion, rats were injected phate stores, restitution of low levels of intracellular inor­ intraperitoneally twice daily for 5 days with 5 mg/kg body ganic phosphate and recovery of left ventricular function weight of this drug. The heart was then isolated and and coronary flow. Intracellular pH recovered rapidly to perfused by the Langendorff technique. Phosphorus-31 preischemic levels, whereas in untreated hearts a complex nucIear magnetic resonance spectroscopy was used to mon­ intracellular inorganic phosphate peak indicated the exist­ itor myocard ia I energy metabolism and intracellular pH ence of areas of different pH within the myocardium. during con trol perfusion and 30 min of total ischemia It is concIuded that anipamil pretreatment protects the (37°C), followed by 30 min of reperfusion. heart against some of the deleterious effects of ischemia and Pretreatment with anipamil altered neither left ventri­ reperfusion. Because this protection occurred in the ab­ cular developed pressure under normoxic conditions nor sence of a negative inotropic effect during normoxia, it the rate and extent of depletion of adenosine triphosphate cannot be attributed to an energy-sparing effect during (ATP) and creatine phosphate during ischemia.
    [Show full text]